Avacopan + Placebo
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Granulomatosis With Polyangiitis
Conditions
Granulomatosis With Polyangiitis, Wegener's, GPA
Trial Timeline
Jul 1, 2026 → Oct 1, 2030
NCT ID
NCT07176546About Avacopan + Placebo
Avacopan + Placebo is a phase 2/3 stage product being developed by Amgen for Granulomatosis With Polyangiitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07176546. Target conditions include Granulomatosis With Polyangiitis, Wegener's, GPA.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07176546 | Phase 2/3 | Recruiting |
Competing Products
9 competing products in Granulomatosis With Polyangiitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NS-229 + Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Tezepelumab + Placebo | AstraZeneca | Phase 2 | 52 |
| Rituximab | Roche | Approved | 85 |
| Rituximab | Roche | Phase 2 | 52 |
| Methylprednisolone + Prednisone + Rituximab | Roche | Approved | 85 |
| Abatacept + placebo | Bristol Myers Squibb | Phase 3 | 76 |
| IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC) | InflaRx | Phase 2 | 44 |
| IFX-1 low dose + IFX-1 high dose + Placebo | InflaRx | Phase 2 | 44 |